Title: I-125 seeds brachytherapy with transcatheter arterial chemoembolization for subcapsular
hepatocellular carcinoma
Version: 0 Date: 14 May 2022
Reviewer's report:
This is a retrospective study with 64 patients enrolled. 32 patients received TACE +
brachytherapy and 32 patients received TACE alone. Several points should be confirmed.
Q1.
Methods: did the authors perform a biopsy on each case according to their diagnosis criteria? If
all the cased were subcapsular HCCs, how to avoid seeding during the biopsy?
Q2.
Methods: how about the size of the microcatheter, and the selectivity of TACE injection?
Q3.
Result: there was a significant difference in the percentage of HBsAg (+) between two groups,
how many patients received antiviral therapy in each group?
Q4.
Result: all patients (n=4) with extrahepatic metastasis in the combined group, how about the
statistic method to manage this problem?
Q5.
Fig.2 The tumor in Fig.2 might not locate at the subcapsular region (<1cm), right? May I have
a coronal view to confirm?
Q6.
Overall. Can the author explain why the benefit of combined therapy in PFS can’t be converted
to OS?
Title: I-125 seeds brachytherapy with transcatheter arterial chemoembolization for subcapsular
hepatocellular carcinoma
Version: 0 Date: 14 May 2022
Reviewer's report:
This is a retrospective study with 64 patients enrolled. 32 patients received TACE +
brachytherapy and 32 patients received TACE alone. Several points should be confirmed.
Q1.
Methods: did the authors perform a biopsy on each case according to their diagnosis criteria? If
all the cased were subcapsular HCCs, how to avoid seeding during the biopsy?
Q2.
Methods: how about the size of the microcatheter, and the selectivity of TACE injection?
Q3.
Result: there was a significant difference in the percentage of HBsAg (+) between two groups,
how many patients received antiviral therapy in each group?
Q4.
Result: all patients (n=4) with extrahepatic metastasis in the combined group, how about the
statistic method to manage this problem?
Q5.
Fig.2 The tumor in Fig.2 might not locate at the subcapsular region (<1cm), right? May I have
a coronal view to confirm?
Q6.
Overall. Can the author explain why the benefit of combined therapy in PFS can’t be converted
to OS?
Please review this paper.
user
Title: I-125 seeds brachytherapy with transcatheter arterial chemoembolization for subcapsular
hepatocellular carcinoma
Version: 0 Date: 14 May 2022
Reviewer's report:
This is a retrospective study with 64 patients enrolled. 32 patients received TACE +
brachytherapy and 32 patients received TACE alone. Several points should be confirmed.
Q1.
Methods: did the authors perform a biopsy on each case according to their diagnosis criteria? If
all the cased were subcapsular HCCs, how to avoid seeding during the biopsy?
Q2.
Methods: how about the size of the microcatheter, and the selectivity of TACE injection?
Q3.
Result: there was a significant difference in the percentage of HBsAg (+) between two groups,
how many patients received antiviral therapy in each group?
Q4.
Result: all patients (n=4) with extrahepatic metastasis in the combined group, how about the
statistic method to manage this problem?
Q5.
Fig.2 The tumor in Fig.2 might not locate at the subcapsular region (<1cm), right? May I have
a coronal view to confirm?
Q6.
Overall. Can the author explain why the benefit of combined therapy in PFS can’t be converted
to OS?
assistant